tetano
Editor, Senior Moderator
Br J Dermatol
. 2021 May 12.
doi: 10.1111/bjd.20479. Online ahead of print.
Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease
A Al-Janabi[SUP] 1 [/SUP], Z Littlewood[SUP] 1 [/SUP], C E M Griffiths[SUP] 1 [/SUP], H J A Hunter[SUP] 1 [/SUP], H Chinoy[SUP] 2 3 4 [/SUP], C Moriarty[SUP] 5 [/SUP], Z Z N Yiu[SUP] 1 [/SUP], R B Warren[SUP] 1 [/SUP]
Affiliations
Abstract
There are few data on whether immunomodulator therapy attenuates humoral response to vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some vaccines require two doses for maximum protection, with international variation in dosing schedules. A 3 month interval between doses is being used in the U.K. We evaluated antibody titres to SARS-CoV-2 following initial-dose BNT162b2 (Pfizer/BioNTech) or AZD1222 (AstraZeneca) vaccines in adults with psoriasis and other immune-mediated inflammatory diseases (IMIDs) receiving biologic and/or oral non-biologic immunomodulators.
. 2021 May 12.
doi: 10.1111/bjd.20479. Online ahead of print.
Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease
A Al-Janabi[SUP] 1 [/SUP], Z Littlewood[SUP] 1 [/SUP], C E M Griffiths[SUP] 1 [/SUP], H J A Hunter[SUP] 1 [/SUP], H Chinoy[SUP] 2 3 4 [/SUP], C Moriarty[SUP] 5 [/SUP], Z Z N Yiu[SUP] 1 [/SUP], R B Warren[SUP] 1 [/SUP]
Affiliations
- PMID: 33982284
- DOI: 10.1111/bjd.20479
Abstract
There are few data on whether immunomodulator therapy attenuates humoral response to vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some vaccines require two doses for maximum protection, with international variation in dosing schedules. A 3 month interval between doses is being used in the U.K. We evaluated antibody titres to SARS-CoV-2 following initial-dose BNT162b2 (Pfizer/BioNTech) or AZD1222 (AstraZeneca) vaccines in adults with psoriasis and other immune-mediated inflammatory diseases (IMIDs) receiving biologic and/or oral non-biologic immunomodulators.